Brett E. Houk

5.9k total citations
49 papers, 1.6k citations indexed

About

Brett E. Houk is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Brett E. Houk has authored 49 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 22 papers in Pulmonary and Respiratory Medicine and 21 papers in Oncology. Recurrent topics in Brett E. Houk's work include Renal cell carcinoma treatment (9 papers), PI3K/AKT/mTOR signaling in cancer (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Brett E. Houk is often cited by papers focused on Renal cell carcinoma treatment (9 papers), PI3K/AKT/mTOR signaling in cancer (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Brett E. Houk collaborates with scholars based in United States, Spain and Italy. Brett E. Houk's co-authors include Carlo L. Bello, Robert J. Motzer, Bill Poland, Lee S. Rosen, George D. Demetri, Michael Amantea, Dongwoo Kang, Kristen J. Pierce, Günther Hochhaus and Jeffrey A. Hughes and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Brett E. Houk

45 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brett E. Houk United States	17	950	711	606	247	163	49	1.6k
Sophia Abraham United States	8	832 0.9×	491 0.7×	569 0.9×	201 0.8×	118 0.7×	12	1.6k
Laurie Sherman United States	15	1.2k 1.3×	474 0.7×	1.0k 1.7×	188 0.8×	149 0.9×	41	1.9k
Remy B. Verheijen Netherlands	18	542 0.6×	794 1.1×	630 1.0×	182 0.7×	180 1.1×	50	1.4k
Paul K. Stockman United Kingdom	21	807 0.8×	737 1.0×	935 1.5×	146 0.6×	68 0.4×	39	1.9k
Tinya J. Abrams United States	12	936 1.0×	824 1.2×	835 1.4×	322 1.3×	211 1.3×	17	2.1k
Katherine Liau United States	19	861 0.9×	843 1.2×	1.1k 1.8×	441 1.8×	71 0.4×	36	2.0k
Leslie B. Lee United States	13	1.0k 1.1×	988 1.4×	790 1.3×	325 1.3×	284 1.7×	13	2.3k
Nicoletta Brega United States	16	995 1.0×	804 1.1×	825 1.4×	301 1.2×	279 1.7×	52	2.1k
Harold Keer United States	21	1.3k 1.4×	1.2k 1.7×	627 1.0×	610 2.5×	53 0.3×	75	2.6k
Susan Ellard Canada	27	823 0.9×	964 1.4×	968 1.6×	526 2.1×	65 0.4×	81	2.4k

Countries citing papers authored by Brett E. Houk

Since Specialization

Citations

This map shows the geographic impact of Brett E. Houk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brett E. Houk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brett E. Houk more than expected).

Fields of papers citing papers by Brett E. Houk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brett E. Houk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brett E. Houk. The network helps show where Brett E. Houk may publish in the future.

Co-authorship network of co-authors of Brett E. Houk

This figure shows the co-authorship network connecting the top 25 collaborators of Brett E. Houk. A scholar is included among the top collaborators of Brett E. Houk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brett E. Houk. Brett E. Houk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Minocha, Mukul, et al.. (2025). Tarlatamab Exposure–Efficacy and Exposure–Safety Relationships to Inform Dose Selection in Patients with Small Cell Lung Cancer. Clinical Cancer Research. 31(22). 4688–4697.

Kong, Stephanie M.Y., Mukul Minocha, Po‐Wei Chen, et al.. (2025). Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer. Clinical Pharmacokinetics. 64(5). 729–741. 3 indexed citations

Houk, Brett E., et al.. (2025). Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRASG12C Mutation from Phase 1 and Phase 2 Studies. The AAPS Journal. 27(1). 26–26.

Xie, Yong, et al.. (2024). Relative Bioavailability of Sotorasib Following Administration as a Water Dispersion to Healthy Subjects and Compatibility With Enteral Administration. Clinical Pharmacology in Drug Development. 14(1). 44–49. 2 indexed citations

Minocha, Mukul, Corbin G. Thompson, Yanchen Zhou, et al.. (2024). Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study. Clinical Pharmacokinetics. 63(12). 1757–1768. 5 indexed citations

Abuqayyas, Lubna, Po‐Wei Chen, Jane R. Parnes, et al.. (2023). Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical Trials. Clinical Pharmacology & Therapeutics. 114(2). 371–380. 12 indexed citations

Wahlstrom, Jan L., et al.. (2022). Impact of Sotorasib on the Pharmacokinetics and Pharmacodynamics of Metformin, a MATE1/2K Substrate, in Healthy Subjects. Clinical Pharmacokinetics. 62(2). 267–275. 6 indexed citations

Dahal, Upendra P., Zhe Wang, Xiaomeng Shen, et al.. (2022). Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate. Cancer Chemotherapy and Pharmacology. 90(4). 357–367. 15 indexed citations

Wainberg, Zev A., María Alsina, Heloisa P. Soares, et al.. (2017). A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Targeted Oncology. 12(6). 775–785. 79 indexed citations

10.

Campo, Josep M. del, Michael J. Birrer, Craig B. Davis, et al.. (2016). A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecologic Oncology. 142(1). 62–69. 82 indexed citations

11.

Shapiro, Geoffrey I., Katherine M. Bell‐McGuinn, Julian R. Molina, et al.. (2015). First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clinical Cancer Research. 21(8). 1888–1895. 97 indexed citations

12.

Jones, Suzanne F., Lillian L. Siu, Johanna C. Bendell, et al.. (2015). A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Investigational New Drugs. 33(5). 1100–1107. 125 indexed citations

13.

Claret, Laurent, François Mercier, Brett E. Houk, Peter A. Milligan, & René Bruno. (2015). Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients. Cancer Chemotherapy and Pharmacology. 76(3). 567–573. 20 indexed citations

14.

Rajan, Arun, Ronan J. Kelly, Jane B. Trepel, et al.. (2011). A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. Clinical Cancer Research. 17(21). 6831–6839. 107 indexed citations

15.

Tomita, Yoshihiko, Nobuo Shinohara, Takeshi Yuasa, et al.. (2010). Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma. Japanese Journal of Clinical Oncology. 40(12). 1166–1172. 100 indexed citations

16.

Houk, Brett E., Carlo L. Bello, Bill Poland, et al.. (2009). Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemotherapy and Pharmacology. 66(2). 357–371. 384 indexed citations

17.

Houk, Brett E., Carlo L. Bello, George D. Demetri, et al.. (2008). Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches. Cancer Research. 68. 5828–5828. 4 indexed citations

18.

Houk, Brett E., Carlo L. Bello, M. Dror Michaelson, et al.. (2007). 4505 ORAL A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure–response for sunitinib in metastatic renal cell carcinoma (mRCC). European Journal of Cancer Supplements. 5(4). 300–300. 6 indexed citations

19.

Houk, Brett E., Roberta E. Martin, Günther Hochhaus, & Jeffrey A. Hughes. (2001). Pharmacokinetics of Plasmid DNA in the Rat. Pharmaceutical Research. 18(1). 67–74. 32 indexed citations

20.

Houk, Brett E., Günther Hochhaus, & Jeffrey A. Hughes. (1999). Kinetic modeling of plasmid DNA degradation in rat plasma. PubMed. 1(3). 15–20. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact